Related Experiment Video
Updated: Jan 23, 2026
Author Spotlight: A Personalized Approach Towards Investigating Alzheimer's Disease Using an In Vitro Blood-Brain Barrier Model
Published on: October 20, 2023
Beta-3 adrenoceptors: A potential therapeutic target for heart disease
Gizem Kayki-Mutlu1, Irem Karaomerlioglu1, Ebru Arioglu-Inan1
1Department of Pharmacology, Faculty of Pharmacy, Ankara University, 06100, Tandogan, Ankara, Turkey.
Insights
Heart failure (HF) involves sympathetic overactivation of beta-1/beta-2 adrenoceptors (β1/β2-ARs). Beta-3 adrenoceptors (β3-ARs) show promise for HF treatment due to their resistance to desensitization and cardioprotective effects.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Molecular Biology
Background:
- Heart failure (HF) is a global health concern requiring novel therapeutic strategies.
- Persistent sympathetic activation of beta-1/beta-2 adrenoceptors (β1/β2-ARs) contributes to myocardial dysfunction and organ damage in HF.
- Receptor desensitization impairs the efficacy of chronic sympathetic stimulation in HF.
Purpose of the Study:
- To investigate the role of beta-3 adrenoceptors (β3-ARs) as a potential therapeutic target in heart failure.
- To explore the cardioprotective mechanisms associated with β3-AR stimulation in the failing myocardium.
Main Methods:
- Analysis of β3-AR expression in human failing myocardium.
- Investigation of signaling pathways mediating β3-AR effects (antihypertrophic, antioxidant, antifibrotic).
- Review of existing literature on β3-AR function in cardiovascular disease.
Main Results:
- β3-AR expression is upregulated in human failing myocardium, suggesting resistance to desensitization.
- Stimulation of β3-ARs demonstrates cardioprotective effects, including antihypertrophic, antioxidant, and antifibrotic actions.
- These beneficial effects are mediated through various intracellular signaling pathways.
Conclusions:
- β3-ARs represent a promising therapeutic target for heart failure management due to their unique properties.
- Further clinical trials are necessary to validate the therapeutic potential of β3-ARs in heart diseases.
Abstract:
As heart failure (HF) is a growing public health problem worldwide, rapid therapeutic development is required to improve HF management. Decreased myocardial contractility in HF is associated with the persistent sympathetic activation of β1/β2-adrenoceptors (β1/β2-ARs). Although it is initially activated to compensate for a decline in myocardial contractility, it plays a pivotal role in organ damage and functional deterioration over time, resulting in the desensitization of receptors involved. The third β-AR subtype, β3-AR, is resistant to desensitization, and as a result, the expression of this subtype is enhanced in human failing myocardium. In addition, this upregulation and the stimulation of this subtype have been demonstrated to mediate cardioprotective effects such as antihypertrophic, antioxidant and antifibrotic effects via various signaling pathways in different cell types. However, the role of this attractive therapeutic intervention in heart diseases must be clarified through clinical trials.
Related Concept Videos
01:23Rheumatic Heart Disease I: Introduction
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
01:27Adrenergic Receptors (Adrenoceptors): Classification
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
01:21Rheumatic Heart Disease III: Medical Management
01:20Rheumatic Heart Disease IV: Nursing Management
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...